IL17A and COVID-19: Extended analysis of factors, non-routinely used in clinical practice, suggests a high risk of COVID-19-related death overtime in patients with elevated dead lymphocyte counts, decreased early apoptosis of lymphocytes, reduced fraction of CD14+/HLA-Dr+ monocytes, increased JNK expression in PBMCs, elevated IL-17 and decreased PAI-1 serum levels (Fig 4).